Literature DB >> 1710567

Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls.

J B Sun1, T Olsson, W Z Wang, B G Xiao, V Kostulas, S Fredrikson, H P Ekre, H Link.   

Abstract

The pathogenesis of multiple sclerosis (MS) could involve an autoimmune response to proteolipid protein (PLP). Immunization of experimental animals with this major myelin protein can lead to experimental allergic encephalomyelitis. To identify a possible role of PLP as target antigen in MS, we evaluated T cell immunity to PLP in blood and cerebrospinal fluid (CSF) from patients with MS and controls by counting cells which in response to PLP in short-term cultures secreted interferon-gamma. The PLP-specific B cell response was analyzed by counting cells secreting anti-PLP antibodies. PLP-reactive T cells were detected in blood of most MS patients (mean value 1 per 20,408 mononuclear cells), and at 41-fold higher numbers in CSF (mean 1 per 500 CSF cells). Anti-PLP IgG antibody-secreting cells were detected in blood from most MS patients (mean 1 per 30,303 cells), but such cells were 49-fold more frequent in CSF (mean 1 per 625 cells). PLP-reactive T and B cells were also detected in blood and CSF from control patients, but at much lower numbers. A strong and persistent autoimmune response to PLP as well as to other myelin proteins, enriched in CSF, is proposed to be pathogenetically important in MS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710567     DOI: 10.1002/eji.1830210620

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  52 in total

1.  A new cell enzyme-linked immunosorbent assay demonstrates gamma interferon suppression by beta interferon in multiple sclerosis.

Authors:  M Bakhiet; V Ozenci; C Withagen; M Mustafa; S Fredrikson; H Link
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  How defects in central tolerance impinge on a deficiency in regulatory T cells.

Authors:  Zhibin Chen; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

4.  The myelin basic protein gene is not a major susceptibility locus for multiple sclerosis in Italian patients.

Authors:  M Eoli; M Pandolfo; C Milanese; P Gasparini; A Salmaggi; M Zeviani
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

5.  Co-inhibitory molecules: Controlling the effectors or controlling the controllers?

Authors:  Govindarajan Thangavelu; Christa Smolarchuk; Colin C Anderson
Journal:  Self Nonself       Date:  2010-02-16

6.  Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability.

Authors:  B Yacyshyn; J Meddings; D Sadowski; M B Bowen-Yacyshyn
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Ro/SS-A-reactive B lymphocytes in salivary glands and peripheral blood of patients with Sjögren's syndrome.

Authors:  A Halse; J B Harley; U Kroneld; R Jonsson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 8.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

9.  Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosis.

Authors:  Priscilla W Lee; Yuhong Yang; Michael K Racke; Amy E Lovett-Racke
Journal:  Brain Behav Immun       Date:  2014-12-10       Impact factor: 7.217

10.  Prevention and treatment of experimental autoimmune encephalomyelitis with clonotypic CDR3 peptides: CD4(+) Foxp3(+) T-regulatory cells suppress interleukin-2-dependent expansion of myelin basic protein-specific T cells.

Authors:  Abigail C Buenafe; Shayne Andrew; Michael Afentoulis; Halina Offner; Arthur A Vandenbark
Journal:  Immunology       Date:  2010-01-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.